ABSTRACT
BACKGROUND: Transient lower esophageal sphincter relaxations (TLESRs) induced by gastric distension are modulated by the metabotropic glutamate receptor 5 (mGluR5) that influences the vagal reflex loop. We therefore aimed to examine the effects of the selective mGluR5 antagonist mavoglurant (AFQ056) on the number of TLESRs in dogs and reflux episodes in patients with gastroesophageal reflux disease (GERD). METHODS: In a dog model, the number of meal-induced TLESRs was determined after intravenous (0.03, 0.1, 0.3, and 1 mg kg-1 ) and oral (1, 3, and 10 mg kg-1 ) doses of mavoglurant with reference to vehicle. In a multicenter, randomized, double-blind, placebo-controlled, three-period crossover study, the incidence of meal-induced reflux episodes was assessed by esophageal impedance monitoring after single, oral doses of mavoglurant (50 and 400 mg) or baclofen (40 mg) in 30 patients with moderate to severe GERD. KEY RESULTS: In dogs, mavoglurant reduced the number of TLESRs after intravenous and oral administration. In patients with GERD, the incidence of postprandial reflux episodes was significantly lower at a dose of 400 mg mavoglurant (-37.5% ; 90% confidence interval [CI]: -57.8, -17.2), whereas there was no significant difference at 50 mg of mavoglurant compared to placebo. A significantly lower incidence of reflux episodes was also noted with the active comparator baclofen (-50.3%; 90% CI: -66.2, -34.3), thereby validating this study. CONCLUSIONS AND INFERENCES: These data suggest a potential clinical benefit of mGluR5 antagonists such as mavoglurant in patients with GERD, particularly in those with persisting symptoms despite treatment with proton pump inhibitors.
Subject(s)
Gastroesophageal Reflux/drug therapy , Indoles/administration & dosage , Receptor, Metabotropic Glutamate 5/antagonists & inhibitors , Administration, Intravenous , Administration, Oral , Adolescent , Adult , Aged , Animals , Dogs , Double-Blind Method , Esophageal Sphincter, Lower/drug effects , Esophageal Sphincter, Lower/physiopathology , Female , Gastroesophageal Reflux/physiopathology , Humans , Incidence , Male , Middle Aged , Postprandial Period , Treatment Outcome , Young AdultSubject(s)
Adrenergic Uptake Inhibitors/adverse effects , Antidepressive Agents/adverse effects , Cyclopropanes/adverse effects , Depressive Disorder/drug therapy , Selective Serotonin Reuptake Inhibitors/adverse effects , Substance Withdrawal Syndrome/etiology , Adrenergic Uptake Inhibitors/therapeutic use , Antidepressive Agents/therapeutic use , Cyclopropanes/therapeutic use , Double-Blind Method , Follow-Up Studies , Humans , Milnacipran , Paroxetine/adverse effects , Paroxetine/therapeutic use , Risk Factors , Selective Serotonin Reuptake Inhibitors/therapeutic use , Treatment OutcomeABSTRACT
To compare the efficacy and assess the tolerability of milnacipran 50mg p.o. b.i.d. to placebo in the prevention of recurrence in depressed patients who had responded an acute treatment and had remained in remission during a 4-month continuation phase. Remission criteria were: a Hamilton Depression Rating Scale (HDRS) (21-item) < or = 8, improvement or disappearance of the initial symptoms, and an assessment of 'very much improved' or 'much improved' on the Clinical Global Impression (CGI) Subscale: Global Improvement. Recurrence was defined by a major depressive episode according to DSM-III-R criteria and a minimum score of 18 on the HDRS, with the need to treat the recurrence. The primary analysis was the rate of recurrence as a function of time in the intent-to-treat population. Groups were compared using the Cox model. Absolute recurrence rates were 16.3% (17/104) in milnacipran-treated patients and 23.6% (26/110) in placebo-treated patients, with a significant difference in the reduction of recurrence as a function of time (Kaplan Meier Survival Analysis analysis, P < 0.05). There was no difference in tolerability between groups. This study demonstrates that milnacipran is effective with good tolerability in preventing recurrence in major depressive disorder over 1 year in patients with recurrent depression who responded to acute treatment with milnacipran and continued their response for 18 weeks.
Subject(s)
Antidepressive Agents/therapeutic use , Cyclopropanes/therapeutic use , Depressive Disorder/drug therapy , Adult , Antidepressive Agents/administration & dosage , Antidepressive Agents/pharmacology , Cyclopropanes/administration & dosage , Cyclopropanes/pharmacology , Depressive Disorder/prevention & control , Disease Progression , Female , Humans , Male , Middle Aged , Milnacipran , Recurrence , Treatment OutcomeABSTRACT
The novel antidepressant agent milnacipran is a dual and equipotent serotonin and noradrenaline reuptake inhibitor. The aim of this double-blind study was to compare the efficacy and safety of milnacipran (50 mg twice daily) with that of imipramine (50 mg twice daily) in elderly patients with major depressive episode. A total of 219 patients were randomly assigned to 8 weeks of double-blind treatment with either milnacipran or imipramine; 72 patients withdrew from the study. At the end of treatment no significant differences were found between milnacipran and imipramine in antidepressant efficacy. A significantly greater number of side-effects, particularly anticholinergic effects, was observed in the imipramine group. Milnacipran may be preferable to imipramine in elderly depressed patients, as it provides the same antidepressant activity as imipramine with a lower incidence of side-effects, and does not impair cognitive ability.